Shared on06 Aug 25Fair value Increased 9.38%
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.
Shared on23 Apr 25Fair value Decreased 0.47%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 2.90%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 1.90%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 0.94%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 0.47%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 1.61%
AnalystConsensusTarget has decreased revenue growth from 9.4% to 8.1%, decreased profit margin from 18.6% to 16.7% and increased future PE multiple from 7.9x to 9.0x.